These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35927773)

  • 1. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis.
    Lei L; Chen R; Fan L; Zheng W; Wang X
    Ann Palliat Med; 2022 Jul; 11(7):2382-2394. PubMed ID: 35927773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients.
    Xiong W; Xu T; Liu X; Zhang L; Yuan Y
    Cancer; 2024 Apr; 130(S8):1488-1498. PubMed ID: 38271397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.
    Zong Y; Wu J; Shen K
    Oncotarget; 2017 Mar; 8(10):17360-17372. PubMed ID: 28061451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.
    Liu M; Liu S; Yang L; Wang S
    BMC Cancer; 2021 Feb; 21(1):118. PubMed ID: 33541289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    He F; Liu J; Shen X; Wang Z; Li Q; Li G
    Ann Pharmacother; 2022 Aug; 56(8):898-909. PubMed ID: 34963337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis.
    Lee H; Park S; Kang JE; Lee HM; Kim SA; Rhie SJ
    Sci Rep; 2020 Jan; 10(1):530. PubMed ID: 31953463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis.
    Li Y; Lu X; Lin Q; Li W
    J Int Med Res; 2020 Aug; 48(8):300060520943473. PubMed ID: 32762463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
    Martín M; Chacón JI; Antón A; Plazaola A; García-Martínez E; Seguí MA; Sánchez-Rovira P; Palacios J; Calvo L; Esteban C; Espinosa E; Barnadas A; Batista N; Guerrero A; Muñoz M; Romio E; Rodríguez-Martín C; Caballero R; Casas MI; Rojo F; Carrasco E; Antolín S
    Oncologist; 2017 Nov; 22(11):1301-1308. PubMed ID: 28701571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis.
    Tan H; Hu J; Liu S
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):268-277. PubMed ID: 30600739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer.
    Zhang W; Wang Y; He J; Xu Y; Chen R; Wan X; Shi W; Huang X; Xu L; Wang J; Zha X
    Nanomedicine; 2023 Nov; 54():102707. PubMed ID: 37717927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
    Yamamoto S; Maeda N; Nagashima Y; Kubo H; Sato Y; Matsui H; Inoue Y; Shindo Y; Kanekiyo S; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yoshino S; Hazama S; Oka M; Nagano H
    Breast Cancer; 2017 Nov; 24(6):783-789. PubMed ID: 28439763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentially Overestimated Efficacy of Nanoparticle Albumin-bound Paclitaxel compared with Solvent-based Paclitaxel in Breast Cancer: A Systemic Review and Meta-analysis.
    Li BX; Chen XJ; Ding TJ; Liu YH; Ma TT; Zhang GL; Wang XM
    J Cancer; 2021; 12(17):5164-5172. PubMed ID: 34335933
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
    Xie Y; Gong C; Zhang J; Wang L; Cao J; Tao Z; Li T; Zhao Y; Li Y; Hu S; Wang B; Hu X
    BMC Cancer; 2021 Nov; 21(1):1174. PubMed ID: 34727875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle albumin-bound paclitaxel versus solvent-based paclitaxel in breast cancer: A protocol for systemic review and meta-analysis.
    Li B; Chen X; Ding T; Liu Y; Ma T; Zhang G; Wang X
    Medicine (Baltimore); 2021 Feb; 100(7):e24514. PubMed ID: 33607781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
    Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F
    Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
    Curr Med Res Opin; 2013 Feb; 29(2):117-25. PubMed ID: 23216340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
    Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of nanopaclitaxel formulation for cancer treatment: evidence from randomized clinical trials.
    Deng X; Huang X; Dong X; Mao G; Xing W
    Nanomedicine (Lond); 2023 Apr; 18(10):833-843. PubMed ID: 37222128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
    Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
    Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis.
    O'Shaughnessy J; Gradishar WJ; Bhar P; Iglesias J
    Breast Cancer Res Treat; 2013 Apr; 138(3):829-37. PubMed ID: 23563958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.